Vir Biotechnology (VIR) Change in Accured Expenses (2018 - 2026)

Vir Biotechnology has disclosed Change in Accured Expenses across 9 years of filings, most recently posting -$17.2 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$17.2 million, down 195.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$44.7 million (down 179.6% YoY), and the FY2025 annual result was -$9.5 million, up 85.15% from the prior year.
• Change in Accured Expenses came in at -$17.2 million for Q1 2026 at Vir Biotechnology, down from $10.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $433.6 million in Q1 2022 to a low of -$288.2 million in Q2 2022.
• The 5-year median for Change in Accured Expenses is -$23.5 million (2025), against an average of -$27.4 million.
• Peak annual rise in Change in Accured Expenses reached 2402.84% in 2022, while the deepest fall reached 8228.76% in 2022.
• Vir Biotechnology's Change in Accured Expenses stood at -$80.7 million in 2022, then jumped by 48.02% to -$41.9 million in 2023, then retreated by 15.65% to -$48.5 million in 2024, then soared by 120.84% to $10.1 million in 2025, then slumped by 270.46% to -$17.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$17.2 million (Q1 2026), $10.1 million (Q4 2025), and -$14.2 million (Q3 2025), per Business Quant data.